174.26

3.87% 6.49

Neurocrine Biosciences Inc (NBIX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$167.77

Aprire:

$169.1

Volume 24 ore:

1.25M

Relative Volume:

1.03

Capitalizzazione di mercato:

$17.52B

Reddito:

$3.10B

Utile/perdita netta:

$668.60M

Rapporto P/E:

26.79

EPS:

6.5044

Flusso di cassa netto:

$831.30M

1 W Prestazione:

+6.14%

1M Prestazione:

+12.54%

6M Prestazione:

+23.94%

1 anno Prestazione:

+34.67%

Intervallo 1D:

$168.26

$174.38

Intervallo di 1 settimana:

$163.12

$174.38

Portata 52W:

$122.14

$174.38

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Nome

Neurocrine Biosciences Inc

Settore

Healthcare (1098)

Industria

Drug Manufacturers - Specialty & Generic (86)

Telefono

(858) 617-7600

Indirizzo

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Dipendente

2,000

Cinguettio

Prossima data di guadagno

2026-07-29

Ultimi documenti SEC

NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NBIX Neurocrine Biosciences Inc	174.26	16.95B	3.10B	668.60M	831.30M	6.5044
TAK Takeda Pharmaceutical Co Adr	16.77	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.82	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.64	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	74.80	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	555.91	23.00B	3.17B	1.29B	1.01B	27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-10-21	Iniziato	Citigroup	Buy
2025-07-21	Iniziato	Truist	Buy
2025-07-10	Iniziato	Goldman	Buy
2025-04-15	Aggiornamento	Needham	Hold → Buy
2025-04-14	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Iniziato	Deutsche Bank	Hold
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-29	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-04-24	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-12-13	Ripresa	Citigroup	Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-21	Reiterato	Mizuho	Neutral
2023-07-24	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-07-06	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-30	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-03-03	Aggiornamento	Evercore ISI	In-line → Outperform
2023-02-03	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Downgrade	Evercore ISI	Outperform → In-line
2022-10-11	Iniziato	UBS	Buy
2022-09-26	Iniziato	Wells Fargo	Equal Weight
2022-06-06	Ripresa	Jefferies	Buy
2022-03-03	Downgrade	Piper Sandler	Overweight → Neutral
2022-02-25	Aggiornamento	Goldman	Neutral → Buy
2022-01-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Iniziato	BMO Capital Markets	Underperform
2021-11-17	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-08-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-05-18	Ripresa	Goldman	Neutral
2021-05-06	Aggiornamento	Barclays	Equal Weight → Overweight
2021-02-02	Iniziato	Raymond James	Outperform
2020-09-30	Iniziato	The Benchmark Company	Hold
2020-08-04	Downgrade	JP Morgan	Overweight → Neutral
2020-06-29	Downgrade	Goldman	Buy → Neutral
2020-06-09	Iniziato	Wedbush	Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-02-24	Iniziato	William Blair	Outperform
2020-02-06	Iniziato	Mizuho	Neutral
2020-02-05	Reiterato	H.C. Wainwright	Buy
2019-12-13	Downgrade	Credit Suisse	Outperform → Neutral
2019-08-07	Iniziato	RBC Capital Mkts	Outperform
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-05	Iniziato	Guggenheim	Neutral
2019-05-21	Iniziato	Credit Suisse	Outperform
2019-04-22	Aggiornamento	JP Morgan	Neutral → Overweight
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-02-06	Reiterato	BofA/Merrill	Buy
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-12-13	Iniziato	Goldman	Buy
2018-11-21	Iniziato	Canaccord Genuity	Buy

Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

Jul 01, 2026

What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders - simplywall.st

Jul 01, 2026

Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia - Yahoo Finance

Jul 01, 2026

Neurocrine starts phase 2 trial of crinecerfont in infants with CAH - Investing.com

Jul 01, 2026

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia - PR Newswire

Jul 01, 2026

Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know - Yahoo Finance

Jul 01, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup - ChartMill

Jul 01, 2026

Jun 30, 2026

Price to book forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView

Jun 30, 2026

Neurocrine (NBIX) legal chief exercises options and sells 10,000 shares - Stock Titan

Jun 30, 2026

Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says - Moomoo

Jun 30, 2026

Price to book forward of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView

Jun 30, 2026

UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $208 - Moomoo

Jun 30, 2026

Jun 29, 2026

9,800-share Form 144 filed for NBIX (NASDAQ: NBIX) - Stock Titan

Jun 29, 2026

Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day - The Globe and Mail

Jun 29, 2026

Neurocrine Biosciences stock hits all-time high at 169.62 USD By Investing.com - Investing.com Australia

Jun 29, 2026

Neurocrine Biosciences stock hits all-time high at 169.62 USD - Investing.com

Jun 29, 2026

Bull of the Day: Neurocrine Biosciences (NBIX) - Zacks Investment Research

Jun 29, 2026

Jun 28, 2026

Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com

Jun 28, 2026

Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance

Jun 28, 2026

Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance

Jun 28, 2026

Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st

Jun 28, 2026

Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now - Insider Monkey

Jun 28, 2026

Jun 27, 2026

Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now - Insider Monkey

Jun 27, 2026

Jun 26, 2026

Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX) - TradingView

Jun 26, 2026

Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June - Investing.com UK

Jun 26, 2026

Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com - Investing.com Australia

Jun 26, 2026

Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView

Jun 26, 2026

Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView

Jun 26, 2026